BofA warns Fed risks policy mistake with early rate cuts
In recent transactions disclosed by Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), Chief Accounting Officer Steven P. Coen executed a sale of company stock. On March 4, Coen sold 395 shares of Class A Common Stock at an average price of $7.725 per share, totaling approximately $3,051. According to InvestingPro data, the stock has shown mixed performance, surging 46% over the past six months despite being down 83% year-over-year. The company, currently valued at $427M, appears undervalued based on InvestingPro’s Fair Value analysis.
Additionally, on March 3, Coen acquired a total of 743 shares through the vesting of Restricted Stock Units, which did not involve any cash transactions. These acquisitions increased his total holdings to 8,407 shares prior to the subsequent sale. The transactions were primarily related to covering tax withholding obligations associated with the vesting of restricted stock units, as per the company’s equity incentive plans. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 5.62, indicating robust short-term financial health. Discover 10+ additional exclusive insights and detailed valuation metrics with InvestingPro’s comprehensive research report.
In other recent news, Ginkgo Bioworks reported its Q4 2024 earnings, showcasing a 29% year-over-year increase in cell engineering revenue, reaching $35 million. Despite this growth, the company faced a significant stock price decline in aftermarket trading, suggesting investor caution. Ginkgo Bioworks also noted a substantial improvement in adjusted EBITDA, with losses reduced from $101 million in Q4 2023 to $57 million in Q4 2024, alongside a significant reduction in cash burn. The company maintains a strong cash position, ending the quarter with $562 million. For 2025, Ginkgo Bioworks provided revenue guidance between $160 and $180 million, with expectations for cell engineering revenue ranging from $110 to $130 million. The company aims to achieve adjusted EBITDA breakeven by the end of 2026. Analyst firms have not provided new upgrades or downgrades, but the company’s future strategies include new product launches and AI-driven data services as potential growth drivers. The firm remains cautious about government contracts, which could influence its biosecurity revenue, projected to be at least $50 million for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.